Validation and feasibility of a postal system for remote monitoring of HbA1c.
COVID-19
HbA1c
diabetes mellitus type 1
diabetes mellitus type 2
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
05
08
2021
accepted:
17
10
2021
entrez:
16
11
2021
pubmed:
17
11
2021
medline:
20
11
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has reduced the accessibility to hemoglobin A1c (HbA1c) tests required for virtual diabetes clinics. The aim was to develop and validate a user-friendly postal system for remote HbA1c monitoring. Validation: A total of 123 capillary blood samples from people with diabetes (PWD) needing face-to-face consultations along with healthy volunteers were measured on a point-of-care (POC) Siemens DCA Vantage Analyzer. Another sample of 5-10 drops was simultaneously collected in a K2EDTA tube (BD Microtainer) and stored for up to 12 days at room temperature for subsequent retesting. Feasibility: During October to December 2020, a total of 286 postal HbA1c kits were sent to PWD prior to their virtual consultation. These contained sample collection guidance, the necessary equipment and a feedback form. As per Packing Instruction 650 regulations, these were posted back to the diabetes center for HbA1c testing on the POC analyzer. There was a strong correlation between the first and the stored sample (R A robust user-friendly postal HbA1c system has been created and successfully integrated into clinical practice using the existing POC equipment at the diabetes center. It provides accurate HbA1c results and is an invaluable tool for remote monitoring of HbA1c in PWD-both during and after the pandemic.
Identifiants
pubmed: 34782336
pii: 9/2/e002527
doi: 10.1136/bmjdrc-2021-002527
pmc: PMC8593276
pii:
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Diabet Med. 2020 Sep;37(9):1463-1470
pubmed: 31418916
Clin Chem. 1983 Jun;29(6):1080-2
pubmed: 6851097
BMC Clin Pathol. 2015 Jul 08;15:13
pubmed: 26157353
J Diabetes Sci Technol. 2010 Mar 01;4(2):244-9
pubmed: 20307383
Diabetes Technol Ther. 2012 Mar;14(3):271-5
pubmed: 22032202
Diabetes Technol Ther. 2021 Aug;23(8):537-545
pubmed: 33826420
BMC Clin Pathol. 2014 May 12;14:21
pubmed: 25045323
Clin Chem Lab Med. 2017 Mar 1;55(3):462-469
pubmed: 27732552
Clin Chem Lab Med. 2009;47(10):1259-64
pubmed: 19751141